ADC Therapeutics SA (NYSE:ADCT) Q2 2024 Earnings Call Transcript
Operator: Welcome to the ADC Therapeutics Second Quarter 2024 Financial Results Conference Call. My name is Didi, and I will be your operator for today's call.
Adc Therapeutics Sa (ADCT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 15,269,217 | $48,250,726 | 2.91% | |
| 2. | Prosight Capital Lawrence Hawkins | 9,570,000 | $30,241,200 | +36% | 9.03% |
| 3. | OrbiMed Advisors Samuel Isaly | 4,316,824 | $13,641,164 | 0.26% | |
| 4. | SilverArc Capital Devesh Gandhi | 1,768,770 | $5,589,313 | +253% | 1.31% |
| 5. | Platinum Asset Management Kerr Neilson | 1,296,153 | $4,095,843 | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.81 | 400,000 | Large Shareholder | 12,995,040 | 2024-07-01 | Filing | |
| $2.81 | 400,000 | Large Shareholder | 15,669,217 | 2024-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.89 | 6,995 | Director | 53,005 | 2024-06-17 | Filing | |
| $2.89 | 6,995 | Director | 79,502 | 2024-06-17 | Filing | |
| $2.89 | 1,193 | Director | 182,644 | 2024-06-17 | Filing | |
| $2.89 | 1,437 | Director | 106,627 | 2024-06-17 | Filing | |
| $2.89 | 1,437 | Director | 213,900 | 2024-06-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,525,741 | $2,532,730 | 0% | |
| 2. | 1,459,514 | $2,422,793 | 0% | |
| 3. | 1,013,540 | $1,682,476 | 0.3% | |
| 4. | 850,737 | $1,412,224 | 0.94% | |
| 5. | 781,937 | $1,298,016 | 0% |
News See All
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
ADC Therapeutics SA reports earnings inline with expectations. Reported EPS is $-0.56 EPS, expectations were $-0.56.
ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript
ADC Therapeutics SA misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.47.
5 Top Performing European Stocks So Far in 2024
In this piece, we will take a look at the five top performing European stocks so far in 2024.
ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript
Operator: Welcome to the ADC Therapeutics Third Quarter 2023 Financial Results Conference Call. My name is Cathy and I will be your operator for today's call.
ADC Therapeutics SA (NYSE:ADCT) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to the ADC Therapeutics Second Quarter 2023 Financial Results Conference Call. My name is Corey, and I'll be your operator for today's call.
ADC Therapeutics SA (NYSE:ADCT) Q4 2022 Earnings Call Transcript
Operator: Welcome to the ADC Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Andrew, and I'll be your operator for today's call.
ADC Therapeutics SA (NYSE:ADCT) Q3 2022 Earnings Call Transcript
Operator: Welcome to the ADC Therapeutics Third Quarter 2022 Financial Results Conference Call. My name is Kevin, and I'll be your operator for today's call.
5 Best Stocks to Buy Under $20 According to Jeremy Green's Redmile Group
In this piece, we will take a look at the top five best stocks to buy under $20 according to Jeremy Green's Redmile Group.
Top 5 Biotech Stocks to Buy According to Jeremy Green's Redmile Group
In this article, we discuss the top 5 biotech stocks to buy according to Jeremy Green's Redmile Group.
Billionaire Hedge Funds
